Purpose: Colorectal cancer (CRC) is one of the major health problems of the Western world and the proportion of elderly patients with CRC is growing. Raltitrexed ('Tomudex'), a specific thymidylate synthase inhibitor, has shown efficacy and manageable toxicity in elderly CRC patients. In this retrospective study, the tolerability of raltitrexed in patients with CRC was examined in relation to age. Patients and Methods: Toxicity parameters, graded according to World Health Organization criteria, were assessed in two patient groups: <70 and greater than or equal to70 years old. In total, 56% (50 out of 90) of patients treated with raltitrexed (3 mg/m(2) as a 15-minute intravenous infusion every 3 weeks) were aged >70 years (M:F 28:22; Eastern Cooperative Oncology Group performance status 0-1:2 38:12). Results: Overall, 437 cycles of chemotherapy were administered and grade 3-4 toxicity was reported in <10% of patients. There were no clinically significant differences between the two age groups, apart from grade 3-4 asthenia, which was reported by 6% and 0% of patients aged 2:70 and <70 years, respectively. This was in spite of a significantly lower calculated mean creatinine clearance in patients aged greater than or equal to70 years compared with those patients <70 years of age. Conclusion: The raltitrexed toxicity profile does not appear to be significantly influenced by age; however caution is recommended in the management of elderly patients, particularly in the presence of impaired renal function.
Tolerability of raltitrexed ('Tomudex') in elderly patients with colorectal cancer
Tonini G;Santini D;Vincenzi B;
2002-01-01
Abstract
Purpose: Colorectal cancer (CRC) is one of the major health problems of the Western world and the proportion of elderly patients with CRC is growing. Raltitrexed ('Tomudex'), a specific thymidylate synthase inhibitor, has shown efficacy and manageable toxicity in elderly CRC patients. In this retrospective study, the tolerability of raltitrexed in patients with CRC was examined in relation to age. Patients and Methods: Toxicity parameters, graded according to World Health Organization criteria, were assessed in two patient groups: <70 and greater than or equal to70 years old. In total, 56% (50 out of 90) of patients treated with raltitrexed (3 mg/m(2) as a 15-minute intravenous infusion every 3 weeks) were aged >70 years (M:F 28:22; Eastern Cooperative Oncology Group performance status 0-1:2 38:12). Results: Overall, 437 cycles of chemotherapy were administered and grade 3-4 toxicity was reported in <10% of patients. There were no clinically significant differences between the two age groups, apart from grade 3-4 asthenia, which was reported by 6% and 0% of patients aged 2:70 and <70 years, respectively. This was in spite of a significantly lower calculated mean creatinine clearance in patients aged greater than or equal to70 years compared with those patients <70 years of age. Conclusion: The raltitrexed toxicity profile does not appear to be significantly influenced by age; however caution is recommended in the management of elderly patients, particularly in the presence of impaired renal function.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
